Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H12O8 |
| Molecular Weight | 308.2403 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(O)CC2=C(CO1)C(=O)C3=C(O2)C=C(O)C(O)=C3C(O)=O
InChI
InChIKey=FCYKAQOGGFGCMD-UHFFFAOYSA-N
InChI=1S/C14H12O8/c1-14(20)3-8-5(4-21-14)11(16)9-7(22-8)2-6(15)12(17)10(9)13(18)19/h2,15,17,20H,3-4H2,1H3,(H,18,19)
Fulvic acid is primarily studied for its effects on plants and soil. Fulvic acid is an organic and natural electrolyte. Depending on the situation, Fulvic acid can act as an electron donor or acceptor and an oxidizer or reducer. Fulvic acid has exhibited the ability to enhance the availability and adsorption of nutrients as well as prolong their time of residence. In the chick animal model Fulvic acid disturbed the processing of procollagen II in articular cartilage. Fulvic acid has being shown to attenuate homocysteine-induced cyclooxygenase-2 expression in human monocytes. Fulvic acid, the main active principle of Shilajit (a natural substance found mainly in the Himalayas), blocks tau self-aggregation, opening an avenue toward the study of Alzheimer's therapy. People take fulvic acid by mouth for brain disorders such as Alzheimer’s disease, as well as respiratory tract infections, cancer, fatigue, heavy metal toxicity, and preventing a condition in which the body tissues do not receive enough oxygen (hypoxia).
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Selenium deficiency and fulvic acid supplementation induces fibrosis of cartilage and disturbs subchondral ossification in knee joints of mice: an animal model study of Kashin-Beck disease. | 1993 |
|
| Fulvic acid supplementation and selenium deficiency disturb the structural integrity of mouse skeletal tissue. An animal model to study the molecular defects of Kashin-Beck disease. | 1993 Feb 1 |
|
| The role of humic substances in drinking water in Kashin-Beck disease in China. | 1999 Apr |
|
| Influence of fulvic acid on the collagen secretion of bovine chondrocytes in vitro. | 1999 Jul |
|
| Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. | 2011 |
|
| Microarray analysis of immediate-type allergy in KU812 cells in response to fulvic acid. | 2011 Mar |
|
| The effect of fulvic acid on pre- and postaggregation state of Aβ(17-42): molecular dynamics simulation studies. | 2013 Jan |
|
| Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs. | 2013 Oct 28 |
|
| Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. | 2013 Sep 24 |
|
| Fulvic acid attenuates homocysteine-induced cyclooxygenase-2 expression in human monocytes. | 2015 Mar 13 |
|
| Carbohydrate-derived fulvic acid is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens. | 2015 Oct |
Patents
Sample Use Guides
Fulvic Acid comes in liquid and powder form: The recommended maintenance dose of Fulvic acid is 1 - 2 Ounces per day based on one teaspoon per 20 pounds (preferably split ½ in the morning and ½ in the mid-afternoon) – 6 teaspoons = 1 ounce = 2 Tablespoons.
Route of Administration:
Oral
To test the effects of Fulvic acid (FA) on homocysteine-induced COX-2
expression in monocytes, human primary monocytes and
U937 cells were pretreated with FA at concentrations of
0.5, 1, 5, and 10 ug/mL for 4 h, and then stimulated with
homocysteine (200 uM) for 4 h in the presence of FA. Pretreating monocytes
with FA at a concentration of 1 or 10 ug/mL
reduced the homocysteine-induced PGE2 secretion.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
1807 (Number of products:114)
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB128622
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
5359407
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
C005023
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
XII14C5FXV
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
100000154409
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
XII14C5FXV
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
1314310
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | RxNorm | ||
|
479-66-3
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
DTXSID00861991
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
